瑞巴派特联合左氧氟沙星、地塞米松保留灌肠治疗溃疡性结肠炎疗效观察

目的:观察瑞巴派特联合左氧氟沙星、地塞米松保留灌肠疗法对溃疡性结肠炎(UC)的临床疗效及安全性.方法:选择44例UC患者随机分为治疗组和对照组,治疗组应用瑞巴派特联合左氧氟沙星、地塞米松保留灌肠治疗,对照组应用左氧氟沙星、地塞米松灌肠治疗.结果:治疗组患者总有效率(90.9%)明显高于对照组(63.6%),P<0.05...     

瑞巴派特保留灌肠治疗溃疡性结肠炎临床疗效

目的：观察瑞巴派特保留灌肠治疗溃疡性结肠炎（uc）的临床疗效及安全性。方法：随机将128例UC患者分成A、B两组,两组均给与奥沙拉嗪常规治疗,A组患者用瑞巴派特保留灌肠,B组用复方锡类散液保留灌肠治疗。结果：A组患者有效率（93．75％）明显高于B组（81．25％）（P〈0．05）,未见明显不良反应。结论：瑞巴派特保留灌肠能有效保护UC患者结肠黏膜并促进溃疡愈合,不良反应少,联合奥沙拉嗪能有效治疗溃疡性结肠炎。     

5-氨基水杨酸保留灌肠治疗慢性溃疡性结肠炎280例观察

目的探讨5-氨基水杨酸保留灌肠治疗慢性溃疡性结肠炎的临床效果。方法分别采用5-氨基水杨酸保留灌肠（0.9%NaCl-60ml＋5-氨基水杨酸制剂4 g,保留灌肠,Qd）和常规治疗法（0.9%NaCl-60ml＋氢化可的松100mg,保留灌肠,Qd）对慢性溃疡性结肠炎患者进行治疗,比较其治疗效果。结果 5-氨基水杨酸保留灌肠治疗可加快慢性溃疡性结肠炎患者粘液脓血便及腹泻症状的缓解。但对患者的腹疼症及里急后重症状的治疗,两组方法无明显差异。5-氨基水杨酸保留灌肠治疗法能够有效提高慢性溃疡性结肠炎患者的治疗有效率（其有效率为98.58%）。结论针对慢性溃疡性结肠炎患者采用5-氨基水杨酸保留灌肠治疗,可明显提高患者的治疗有效率,加快部分临床症状的缓解。     

康复新液保留灌肠治疗35例溃疡性结肠炎

目的观察康复新治疗溃疡性结肠炎的临床疗效。方法用康复新液保留灌肠配合口服水杨酸偶氮磺胺吡啶治疗溃疡性结肠炎35例,并与单纯口服水杨酸偶氮磺胺吡啶治疗溃疡性结肠炎20例做对照,比较两组疗效。结果治疗组总有效率94.28%,对照组总有效率85.0%。结论康复新治疗溃疡性结肠炎疗效较好。     

大肠水疗联合西药保留灌肠治疗溃疡性结肠炎疗效观察

目的观察大肠水疗联合西药保留灌肠治疗初发型溃疡性结肠炎的疗效。方法 48例初发型溃疡性结肠炎患者,随机分成两组,观察组24例,对照组24例。在口服柳氮磺胺吡啶（SASP）的基础上,观察组应用大肠水疗联合西药保留灌肠治疗,对照组只用药物保留灌肠治疗,2周为1个疗程,治疗后进行疗效分析。结果观察组的总有效率为91.7%,对照组的总有效率为62.5%。两组比较,差异有统计学意义（P〈0.05）。结论大肠水疗联合西药保留灌肠治疗溃疡性结肠炎疗效优于传统保留灌肠治疗。     

思密达治疗溃疡性结肠炎腹泻的疗效观察

目的探讨思密达灌肠联合美沙拉嗪治疗溃疡性结肠炎及单用美沙拉嗪治疗溃疡性结肠炎疗效对比。方法选取我院2004年1月至2010年6月在我院住院的80例患者分为2组,治疗组40例服用美沙拉嗪1.0g一日3次,思密达9g每晚保留灌肠,对照组40例仅口服美沙拉嗪1.0g一日3次。结果联合治疗组有效率90%,对照组有效率67.5%,两组比较有统计学意义(P<0.05)。结论口服联合药物灌肠治疗溃疡性结肠炎有很好的疗效。     

27例溃疡性结肠炎的治疗护理体会

目的:观察思密达保留灌肠配合口服水杨酸类药物治疗溃疡性结肠炎的效果.方法:选用经电子结肠镜确诊的溃疡性结肠炎患者27例给予水杨酸类药物口服加思密达保留灌肠.结果:27例显效20例,占总数74％,有效7例,占总数26％.结论:口服水杨酸类药物加思密达保留灌肠治疗溃疡性结肠炎疗效可靠.     

思密达、地塞米松和甲哨唑保留灌肠治疗溃疡性结肠炎的疗效分析

目的观察联合应用思密达(蒙脱石散)、地塞米松注射液和甲哨唑注射液保留灌肠治疗溃疡性结肠炎临床疗效。方法选择68例溃疡性结肠炎患者,随机分为治疗组33例,对照组35例。治疗组使用思密达(蒙脱石散)、地塞米松注射液和甲哨唑注射液保留灌肠治疗,对照组使用柳氮磺胺吡啶片保留灌肠治疗,疗程4周。分别统计两组完全缓解例数(完全缓解率)、有效例数(有效率)、无效例数(无效率)以及总有效率。结果治疗组完全缓解17例,有效14例,无效2例,总有效率93.93%。对照组治愈15例,有效11例,无效9例,总有效率74.29%。治疗组和对照组相比,差异具有统计学意义(P<0.05)。结论联合应用思密达(蒙脱石散)、地塞米松和甲哨唑保留灌肠治疗溃疡性结炎具有更好的临床疗效。     

美沙拉嗪口服联合中药灌肠治疗溃疡性结肠炎临床观察

目的观察美沙拉嗪口服联合中药灌肠治疗溃疡性结肠炎的临床疗效。方法 65例患者随机分为治疗组35例,用美沙拉嗪口服联合中药保留灌肠,对照组30例用SASP口服及保留灌肠,观察两组临床症状、结肠黏膜的改善情况及不良反应。结果治疗组和对照组的总有效率分别为94.3%和73.3%,两组临床疗效比较有显著性差异（P〈0.05）,治疗组症状及结肠黏膜的改善情况优于对照组（P〈0.05）,治疗组与对照组的不良反应比较有高度显著性差异（P〈0.01）。结论美沙拉嗪口服联合中药保留灌肠治疗溃疡性结肠炎安全有效。     

康复新液联合思密达保留灌肠治疗48例溃疡性结肠炎

目的观察康复新液联合思密达保留灌肠治疗溃疡性结肠炎的临床疗效。方法用电子结肠镜检查确诊96例溃疡性结肠炎患者,随机均分为A、B组。A组用康复新液 思密达 生理盐水混合后保留灌肠,每天2次;B组用粉碎柳氮磺胺吡啶 思密达 生理盐水混合后保留灌肠,方法同A组。治疗1月后用结肠镜复查,观察治疗效果。结果A、B组总有效率分别为91%、50%,两组有显著性差异(P<0.01)。结论康复新液联合思密达保留灌肠治疗溃疡性结肠炎临床疗效显著。     

思密达与妈咪爱保留灌肠治疗婴幼儿轮状病毒性肠炎疗效观察

目的:观察思密达与妈咪爱保留灌肠治疗婴幼儿轮状病毒性肠炎的疗效.方法:我院儿科2009年10月～2010年12月收治腹泻患儿140例,分为常规思密达、妈咪爱口服对照组70例和思密达、妈咪爱保留灌肠治疗组70例,观察两组患儿疗效.结果:治疗组显效率及总有效率明显优于对照组(P＜0.01).结论:思密达、妈咪爱保留灌肠治疗婴幼儿轮状病毒性肠炎疗效好,未发现不良反应,值得临床推广.     

慢性萎缩性胃炎120例分析

目的探讨瑞巴派特联合叶酸和替硝唑治疗慢性萎缩性胃炎临床疗效。方法以120例慢性萎缩性胃炎为研究对象,采用随机数字表法分为两组,观察组使用瑞巴派特片、叶酸联合替硝唑治疗,对照组使用胶体果胶铋胶囊和克拉霉素治疗。经过4周治疗,比较两组患者的临床疗效。结果观察组的总有效率90％,优于对照组的75％（x2=12．347,P〈0．05）。观察组的Hp转阴率为92％,对照组的幽门螺旋杆菌转阴率为72％,观察组优于对照组（X2=8．647,P〈0．05）。结论瑞巴派特、叶酸联合替硝唑有利于治疗慢性萎缩性胃炎,值得临床推广使用。     

A new mesalazine foam enema (Claversal Foam) compared with a standard liquid enema in patients with active distal ulcerative colitis

BACKGROUND: Rectally administered mesalazine (5-aminosalicylic acid) is a recognized therapy for distal ulcerative colitis. It is frequently applied as a liquid enema. However, there are reasons (acceptability to the patient, more uniform topical dispersion and effective adhesion) to prefer a foam-based enema. AIM: This study compared a foam enema (2 g mesalazine per day, Claversal Foam) with a standard liquid enema (4 g mesalazine per day, Salofalk enema). METHODS: Patients with active distal ulcerative colitis, diagnosed according to standardized criteria, were treated for 4 weeks. The primary goal was clinical remission; endoscopic remission, histological changes, global assessment and standard safety measures were also analysed. A major subset of the patients also provided quality-of-life data. RESULTS: Both foam and liquid enema gave good rates of clinical and endoscopic remission. The foam enema was shown to be as efficacious as the reference, even though the daily dose in the foam treatment contained only half as much active drug as in the reference treatment. Minor regional differences in efficacy were seen. The tolerabilities of the two formulations were comparable. CONCLUSIONS: The foam enema offers a safe, efficacious and acceptable treatment for distal ulcerative colitis.     

Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis

BACKGROUND: Rectally administered mesalazine (mesalamine; 5-aminosalicylic acid) is the first-line therapy for treatment of distal ulcerative colitis. Recently, a high-volume 5-aminosalicylic acid foam has been shown to be as effective and safe as standard 5-aminosalicylic acid enema. AIM: To study the efficacy and safety of a low-volume vs. a high-volume 5-aminosalicylic acid foam. METHODS: In this investigator-blinded study, patients with active distal ulcerative colitis [Clinical Activity Index (CAI) > 4, Endoscopic Index > or = 4] were randomized to receive 2 x 1 g/30 mL low-volume (n = 163) or 2 x 1 g/60 mL high-volume 5-aminosalicylic acid foam (n = 167) for 42 days. Primary end point was clinical remission (CAI < or = 4) at the final/withdrawal visit (per-protocol). RESULTS: 330 patients were evaluable for efficacy and safety by intention-to-treat, 290 for per-protocol analysis. Clinical remission rates at week 6 (per-protocol) were 77% on low-volume foam vs. 77% on high-volume foam (P = 0.00002 for non-inferiority). The low-volume foam was associated with a lower frequency of severe discomfort, pain and retention problems. CONCLUSIONS: Low-volume 5-aminosalicylic acid foam is as effective and safe as a high-volume 5-aminosalicylic acid foam in the treatment of active distal ulcerative colitis, but offers compliance advantages compared to the high-volume preparation.     

Double-blind placebo-controlled multicentre studies of rebamipide, a gastroprotective drug, in the treatment of functional dyspepsia with or without Helicobacter pylori infection

BACKGROUND: Functional dyspepsia is a problem that is difficult to treat in clinical practice. AIM: To evaluate the efficacy and safety of rebamipide (a cytoprotective drug) in functional dyspepsia. METHODS: Patients with functional dyspepsia (n=557) were divided a priori into two studies by Helicobacter pylori status, and enrolled in a 2-week baseline evaluation period. Ninety-nine patients with Helicobacter pylori and 173 patients without Helicobacter pylori, continuing to have at least moderate upper abdominal pain or discomfort, were randomly assigned to rebamipide 100 mg, rebamipide 200 mg or placebo, three times a day, in a double-blind design for 8 weeks. RESULTS: There was significant improvement of individual symptom scores from baseline in all the treatment arms. No significant improvement of individual symptom scores was observed in either rebamipide group at the end of the studies compared to placebo, although the belching score was significantly reduced in the rebamipide 100 mg and 200 mg groups at week 2 (P=0.017 and P=0.012, respectively) in the Helicobacter pylori-positive patients. The ratio of patients who requested usage of the study medication again was greater in the rebamipide 100 mg (85%) and 200 mg (96%, P=0.020) groups compared with the placebo group (72%) among Helicobacter pylori-positive patients. There were no serious study medication related adverse events. CONCLUSIONS: Rebamipide was not superior to placebo in terms of individual symptoms at the end of treatment.     

MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations

Background  Two phase III studies have evaluated mesalazine (mesalamine) with MMX (Multi Matrix System) technology in patients with active mild-to-moderate ulcerative colitis.
Aim  To determine the efficacy of MMX mesalazine for the induction of clinical and endoscopic remission in specific subgroups of patients with active, mild-to-moderate ulcerative colitis.
Methods  Data from two double-blind, placebo-controlled trials were analysed (517 out-patients). Patients were randomized to receive MMX mesalazine [2.4 g/day (once daily or 1.2 g twice daily) or 4.8 g/day (once daily)] or placebo for 8 weeks.
Results  The percentages of patients treated with MMX mesalazine, 2.4 or 4.8 g/day, in clinical and endoscopic remission at week 8 were similar and significantly ( P  < 0.05) greater than placebo in subgroups stratified by disease extent, disease severity and gender and among patients not previously receiving low-dose 5-aminosalicylic acid. Among patients transferring directly from prior low-dose oral 5-aminosalicylic acid, MMX mesalazine 4.8 g/day was significantly ( P  = 0.018) more effective than placebo in inducing clinical and endoscopic remission. Efficacy over placebo did not reach significance in patients transferring directly to MMX mesalazine 2.4 g/day.
Conclusion  MMX mesalazine is effective in active UC regardless of disease extent, disease severity, gender and previous, low-dose, 5-ASA therapy.     

Augmented chondroprotective effect of coadministration of celecoxib and rebamipide in the monosodium iodoacetate rat model of osteoarthritis

Osteoarthritis (OA) is a degenerative joint disease characterized by the progressive loss of articular cartilage and chronic pain. Although cyclooxygenase-2 (COX-2) inhibitors such as celecoxib are recommended to patients at high risk of gastrointestinal (GI) adverse events, COX-2 inhibitors do not completely prevent GI adverse events. Rebamipide, a gastroprotective agent, has anti-inflammatory properties and acts as an oxygen radical scavenger. The aim of this study was to investigate the in vivo effects of coadministration of rebamipide and celecoxib in an OA rat model. OA was induced by intra-articular injection of monosodium iodoacetate. Oral administration of rebamipide was initiated on the day of OA induction. In this study, rebamipide showed antinociceptive properties and attenuated cartilage degeneration. Rebamipide reduced the expression of matrix metalloproteinase 13, interleukin-1β, inducible nitric oxide synthase, and nitrotyrosine in OA cartilage. OA rats treated with celecoxib in combination with rebamipide demonstrated a higher pain threshold than those treated with monotherapy. Histological examination also showed that the joints from OA animals treated with combination therapy demonstrated less cartilage damage than those of animals treated with monotherapy. We showed that the potential benefit of combination therapy with celecoxib and rebamipide on pain and cartilage degeneration in OA.     

Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis

BACKGROUND: Beclomethasone dipropionate (BDP) is a second-generation steroid with topical effects and minimal systemic activity for patients with ulcerative colitis (UC). AIM: To review all available literature to assess the efficacy of enema/foam BDP compared with enema/foam 5-aminosalicylic acid (5-ASA) in the control of left-sided mild-moderate UC. METHODS: We selected randomized controlled trials of enema/foam BDP compared with enema/foam 5-ASA treatment in patients with UC. Two reviewers assessed trial quality and extracted data independently. RESULTS: Four trials involving 428 UC patients, 209 treated with 5-ASA (1-4 g o.d.) and 219 with BDP (3 mg o.d.), were included. Intention-to-treat analysis showed that 5-ASA induced improvement/remission of UC in 146 (69.9%) patients, while BDP in 143 (65.3%). The test for heterogeneity (Cochran Q) was not significant and Mantel-Haenszel pooled estimate of odds ratio was 1.23 (95% CI = 0.82-1.85). The results did not change when analysis was performed on a per-protocol basis. CONCLUSION: The randomized controlled trials identified in this review showed that rectal BDP has equal effect as 5-ASA to control symptoms in UC.